Tizanidine对胶质瘤细胞U251增殖、迁移及凋亡的影响

摘要
图/表
参考文献(20)
相关文章 (0)

全文: PDF (973 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究Tizanidine对胶质瘤细胞U251的增殖、迁移及凋亡的影响，并尝试探讨其作用机制。方法将U251细胞分为两组，一组用Tizanidine（20 μmol/L）处理24 h；另一组用DMSO处理为对照组。采用CCK8实验检测细胞增殖情况；采用Transwell实验检测细胞的迁移和侵袭情况；采用细胞流式检测细胞凋亡情况，采用Western blot检测PI3K-AKT信号通路相关蛋白及凋亡相关蛋白的表达量的变化。结果 CCK8增殖实验表明Tizanidine可以抑制脑胶质瘤细胞U251的增殖（P < 0.05）；Transwell结果说明Tizanidine可以抑制脑胶质瘤细胞U251的迁移和侵袭（P < 0.05）；流式凋亡结果分析显示经无血清凋亡诱导后，经Tizanidine处理的细胞凋亡明显增多（P < 0.05），Western blot 结果显示经过Tizanidine处理的U251细胞，细胞的抗凋亡蛋白B淋巴细胞瘤-2（BCL-2）的表达量显著下调（P < 0.05），促凋亡蛋白Bcl-2相关X蛋白（BAX）和Active Caspase3表达量则显著上调（P < 0.05），AKT和mTOR的磷酸化水平均受到了显著抑制（P < 0.05），PI3K/AKT信号通路的下游蛋白P70、CyclinD1的表达也相应下调（P < 0.05）。结论 Tizanidine抑制胶质瘤细胞U251的增殖、迁移和侵袭，诱导其凋亡，这有可能是通过抑制PI3K/AKT信号通路的激活实现的。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘冰1 霍会永1 冯社军1 曹凌1 赵现1 曹妍1 王如科2 李军涛1

关键词 ： Tizanidine, U251, PI3K/AKT信号通路

Abstract：Objective To investigate the effect of Tizanidine on the proliferation, migration and apoptosis of U251, and to explore its mechanism, as well. Methods U251 cells were divided into two groups, one group treated with Tizanidine (20 μmol/L), and the other treated with DMSO as control group. CCK8 assay was used to detect cell proliferation; Transwell assay was performed to detect cell migration and invasion; flow cytometry was adopted to detect cell apoptosis; Western blot was used to detect the expression of PI3K-AKT signaling-related proteins and apoptosis-related proteins. Results The proliferation of U251 cell was inhibited by Tizanidine (P < 0.05); and Tizanidine treatment also inhibited migration and invasion of U251 cell (P < 0.05); Tizanidine induced apoptosis in U251 cell (P < 0.05); Western blot showed that the expression of Bcl-2 was significantly down-regulated (P < 0.05), and the expression of BAX and Active Caspase3 were both significantly up-regulated in Tizanidine-treated U251 cells (P < 0.05), respectively. In addition, Tizanidine significantly inhibited the phosphorylation levels of AKT and mTOR (P < 0.05), and the expression of related downstream proteins (P70s6k and Cyclin D1) were decreased in U251 cells (P < 0.05). Conclusion Tizanidine inhibits proliferation, migration and invasion, induces apoptosis in U251 cell, which may be achieved by inhibiting activation of the PI3K/AKT signaling pathway.

Key words： Tizanidine U251 PI3K/AKT signaling

通讯作者: 李军涛（1972-），男，主任医师，硕士生导师；研究方向：神经内科常见病诊治。

作者简介: 刘冰（1981-），男，硕士；研究方向：神经内科常见病诊治。

引用本文:

刘冰1 霍会永1 冯社军1 曹凌1 赵现1 曹妍1 王如科2 李军涛1. Tizanidine对胶质瘤细胞U251增殖、迁移及凋亡的影响[J]. 中国医药导报, 2018, 15(2): 27-31.
LIU Bing1 HUO Huiyong1 FENG Shejun1 CAO Ling1 ZHAO Xian1 CAO Yan1 WANG Ruke2 LI Juntao1. Effect of Tizanidine on proliferation, migration and opoptosis of U251 cell. 中国医药导报, 2018, 15(2): 27-31.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I2/27

[1] Dwyer CA，Bi WL，Viapiano MS，et al. Brevican knockdown reduces late-stage glioma tumor aggressiveness [J]. J Neurooncol，2014，120（1）：63-72.
[2] Song Y，Luo Q，Long H，et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth，migration，and invasion in glioma [J]. Mol Cancer，2015，13（1）：235.
[3] Le RE，Taillibert S，Chamberlain MC. Anaplastic glioma：current treatment and management [J]. Expert Rev Neurotherapeutics，2015，15（6）：601-620.
[4] Rd LA，Saper JR. Chronic headache：New advances in treatment strategies[J]. Neurology，2002，59（5 Suppl 2）：S8-S13.
[5] Granfors MT，Backman JT，Laitila J，et al. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro [J]. Br J Clin Pharmacol，2004，57（3）：349-353.
[6] Garside R，Pitt M，Anderson R，et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma：a systematic review and economic evaluation [M]. Health Technol Assess，2007，11（45）：iii-iv，ix-221.
[7] Río-Sancho SD，Merino V，López-Castellano A，et al. A UHPLC-UV Method to Quantify Skin Deposition and Transdermal Permeation of Tizanidine Hydrochloride [J]. J Chromatogr Sci，2016，54（5）：790-795.
[8] Luo J，Manning BD，Cantley LC. Targeting the PI3K-Akt pathway in human cancer：rationale and promise [J]. Cancer Cell，2003，4（4）：257-262.
[9] Vivanco I，Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer [J]. Nat Rev Cancer，2002， 2（7）：489-501.
[10] 程玉，薛晶，次云哲，等.Oct4和PI3K在胃癌组织中的表达变化及意义[J].山东医药，2016，56（34）：27-29.
[11] 张雪群，高卫，潘盼，等.PI3K/AKT及其相关因子在结肠癌中的表达[J].山东大学学报：医学版，2016，54（1）：52-57.
[12] Porta C，Paglino C，Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer [J]. Front Oncol，2014，4（4）：64-68.
[13] Lopiccolo J，Blumenthal GM，Bernstein WB，et al. Targeting the PI3K/Akt/mTOR pathway：effective combinations and clinical considerations [J]. Drug Resist Updat. 2008，11（1）：32-50.
[14] Chang L，Graham PH，Ni J，et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance [J]. Crit Rev Oncol Hematol，2015， 96（3）：507-517.
[15] Yap T，Garrett MM，Raynaud F，et al. Targeting the PI3K-AKT-mTOR pathway：progress，pitfalls，and promises [J]. Curr Opin Pharmacol，2008，8（4）：393-412.
[16] Ben M，Rodrigo D，Josep T. Targeting the PI3K/Akt/mTOR Pathway-Beyond Rapalogs[J]. Oncotarget，2010，1（7）：530-543.
[17] Zhang YH，Zhang J，Song JN，et al. The PI3K-AKT-mTOR pathway activates recovery from general anesthesia [J]. Oncotarget，2016，7（27）：40 939-40 952.
[18] Utermark T，Rao T，Cheng H，et al. The p110{alpha and p110{beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis [J]. Genes Dev，2012，26（14）：1573-1586.
[19] Mabuchi S，Kuroda H，Takahashi R，et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer [J]. Gynecol Oncol，2015，137（1）：173-179.
[20] Li X，Wu C，Chen N，et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma [J]. Oncotarget，2016，7（22）：33 440-33 450.